Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Clinical trial NCT02051218 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02051218
- Sponsor
- Swiss Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-16
- Primary completion
- 2026-06-30
- Enrollment
- 1380
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.